Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children
NCT03013517
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Peanut Allergy
Interventions
DRUG:
Viaskin Peanut 250µg
Sponsor
DBV Technologies